Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
Capsida Biotherapeutics secures $140 million in capital
Capsida Biotherapeutics emerged from stealth mode with $140 million in startup capital, including a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners and $90 million in upfront and equity investment capital from its collaboration agreement with AbbVie.
2021
Capsida announces $50 million Series A financing
Capsida announced a $50 million Series A financing from Versant Ventures and Westlake Village BioPartners.
2021
Capsida and AbbVie announce gene therapy collaboration
Capsida announced a multi-year strategic collaboration and option agreement with AbbVie to develop targeted gene therapies for three central nervous system disease targets. The agreement includes $80 million in upfront cash and a $10 million equity investment for Capsida.
2021
Capsida debuts with $50 million Series A commitment
Capsida Biotherapeutics announced its emergence from stealth mode with a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners.